Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Banares, C. Hernández-García, B. Fernández-Gutiérrez, J.A. Jover.
Eye involvement in the spondyloarthropathies.
Rheum Dis Clin North Am, 24 (1998), pp. 771-784
[2.]
S.M. Van der Linden, H.U. Rentsch, N. Gerber, A. Cats, H.A. Valkenburg.
The association between ankylosing spondylitis, acute anterior uveitis and HLA-B27: the results of a Swiss family study.
Br J Rheumatol, 27 (1988), pp. 39-41
[3.]
S. Muñoz-Fernández, E. Martín Mola.
Cómo, cuándo y qué del tratamiento de la uveítis.
Semin Fund Esp Reumatol, 5 (2004), pp. 169-179
[4.]
S. Muñoz-Fernández, V. Hidalgo, J. Fernández-Melón, A. Schlincker, G. Bonilla, D. Ruiz-Sancho, et al.
Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period.
J Rheumatol, 30 (2003), pp. 1277-1279
[5.]
D.A. Jabs, J.T. Rosembaun, C.S. Foster, G.N. Holland, J.C. Jaffe, J.C. Louie, et al.
Guidelines for the use of immunosuppresive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.
Am L Ophthalm, 130 (2000), pp. 492-513
[6.]
J.R. Smith, J.T. Rosenbaum.
Management of uveitis: a rheumatologic perspective.
Arthritis Rheum, 46 (2002), pp. 309-318
[7.]
L. Pascalis, G. Pia, G. Aresu, T. Frongia, L. Barca.
Combined cyclosporine A-steroid-MTX treatment in endogenous noninfectious uveitis.
J Autoinmun, 6 (1993), pp. 467-480
[8.]
J.R. Smith, R.D. Levinson, G.N. Holland, D.A. Jabs, M.R. Robinson, S.M. Whitcup, et al.
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
Arthritis Rheum, 45 (2001), pp. 252-257
[9.]
A. Reiff, S. Takei, S. Sadeghi, A. Stout, B. Shaham, B. Bernstein, et al.
Etanercept therapy in children with treatment resistant uveitis.
Arthritis Rheum, 44 (2001), pp. 1411-1415
[10.]
Y. El-Shabrawi, J. Hermann.
Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis.
Ophthalmology, 109 (2002), pp. 2342-2346
[12.]
P. Davidson, A.H. Baggenstoss, C.H. Slocumb, G.W. Daugherty.
Cardiac and aortic lesions in rheumatoid spondylitis.
Mayo Clin Proc, 38 (1963), pp. 427-435
[13.]
M. Dougados, J.M. Behier, I. Jolchine, A. Calin, D. Van der Heijde, I. Oliveri, et al.
Efficacy of celecoxib, a ciclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six week controled study with comparison against placebo an against a conventional nosesteriodal antinflammatory drug.
Arthritis Rheum, 44 (2001), pp. 180-185
[14.]
D. Van der Heidje, H.S.B. Baraf, C. Ramos-Remus, A. Colin, A.L. Neawer, M. Schiff, et al.
Evolution of the efficacy of etoricoxib in ankylosing spondilitys: results of a filty-two-week, randomized, controlled study.
Arthritis reum, 52 (2005), pp. 1205-1215
[15.]
D.A. Brewerton, D.G. Gibson, D.H. Goddard, T.J. Jones, R.B. Moore, C.T. Pease, et al.
The myocardium in ankylosing spondylitis. A clinical, echocardiographic, and histopathological study.
Lancet, 1 (1987), pp. 995-998
[16.]
C. Salvarani, I.G. Vlachonikolis, D.M. Van der Heijde, G. Fornaciari, P. Macchioni, M. Beltrami, et al.
Musculoskeletal manifestations in a population- based cohort of inflammatory bowel disease patients.
Scand J Gastroenterol, 36 (2001), pp. 1307-1313
[17.]
H. Mielants, E.M. Veys, C. Cuvelier, M. De Vos.
Course of gut inflammation in spondylarthropathies and therapeutic consequences.
Baillieres Clin Rheumatol, 10 (1996), pp. 147-164
[18.]
J.C. Alonso, F.J. López-Longo, J.L. Lampreave, C.M. González, M. González, I. Almoguera, et al.
Different abdominal scintigraphy pattern in patients with ulcerative colitis, Crohn's disease and seronegative spondylarthropathies.
Br J Rheumatol, 34 (1995), pp. 946-950
[19.]
D. Lamarque, J.T. Nhieu, M. Breban, C. Bernardeau, N. Martín-García, Z. Szepes, et al.
Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis.
J Rheumatol, 30 (2003), pp. 2428-2436
[20.]
F. De Keyser, D. Baeten, F. Van den Bosch, M. De Vos, C. Cuvelier, H. Mielants, et al.
Gut inflammation and spondyloarthropathies.
Curr Rheumatol Rep, 4 (2002), pp. 525-532
[21.]
M.J. Carter, A.J. Lobo, S.P. Travis, IBD Section, British Society of Gastroenterology.
Guidelines for the treatment of inflammatory bowel disease in adults.
Gut, (2004), pp. V1-V15
[22.]
W.J. Sandborn, S.B. Hamaner, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, et al.
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Gastroenterology, 121 (2001), pp. 1242-1246
[23.]
H.M. Van Dullemen, S.J. Van Deventer, D.W. Hammer, H.A. Bjl, J. Jasen, G.N. Tygat, et al.
Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2).
Gastroenterology, 109 (1995), pp. 129-135
[24.]
A. Papadakis, O. Shaye, A. Vasiliauskas, A. Ippoliti, M. Dubinsky, J. Birt, et al.
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Am J Gastroenterol, 100 (2005), pp. 75-79
[25.]
U. Seckin, N. Bolukbasi, G. Gursel, S. Eroz, V. Sepici, N. Ekim.
Relationship between pulmonary function and exercise tolerance in patients with ankylosing spondylitis.
Clin Exp Rheumatol, 18 (2000), pp. 503-506
[26.]
I.P. Casserly, H.M. Fenlon, E. Breatnach, S.M. Sant.
Lung findings on highresolution computed tomography in idiopathic ankylosing spondylitis–Correlation with clinical findings, pulmonary function testing and plain radiography.
Br J Rheumatol, 36 (1997), pp. 677-682
[27.]
D.K. Boushea, W.R. Sundstrom.
The pleuropulmonary manifestations of ankylosing spondylitis.
Semin Arthritis Rheum, 18 (1989), pp. 277-281
[28.]
E.S. Strobel, E. Fritschka.
Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.
Clin Rheumatol, 17 (1998), pp. 524-530
[29.]
M.L. Orme.
Non-steroidal anti-inflammatory drugs and the kidney.
Br Med J (Clin Res Ed), 292 (1986), pp. 1621-1622
[30.]
M.A. Gertz, R.A. Kyle.
Secondary systemic amyloidosis: response and survival in 64 patients.
Medicine (Baltimore), 70 (1991), pp. 246-256
[32.]
C. Geffriaud, L.H. Noel, P. Blanche, D. Ganeval, C. Barbanel, P. Jungers, et al.
Ankylosing spondylitis with type AA amyloidosis. 6 cases.
Presse Med, 17 (1988), pp. 2344-2347
[33.]
Y. Sasatomi, Y. Kiyoshi, N. Uesugi, S. Hisano, S. Takebayashi.
Prognosis of renal amyloidosis: a clinicopathological study using cluster analysis.
Nephron, 87 (2001), pp. 42-49
[34.]
A. Escalante, G.R. Ehresmann, F.P. Quismorio Jr..
Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine.
Arthritis Rheum, 34 (1991), pp. 920-922
[35.]
K. Berglund, C. Keller, H. Thysell.
Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease.
Ann Rheum Dis, 46 (1987), pp. 757-762
[36.]
J.E. Gottenberg, F. Merle-Vincent, F. Bentaberry, Y. Allanore, F. Berenbaum, B. Fautrel, et al.
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
Arthritis Rheum, 48 (2003), pp. 2019-2024
[37.]
K.N. Lai, P.K. Li, B. Hawkins, F.M. Lai.
IgA nephropathy associated with ankylosing spondylitis: occurrence in women as well as in men.
Ann Rheum Dis, 48 (1989), pp. 435-437
[38.]
C. Ramos-Remus, A. Gómez-Vargas, J.L. Guzmán-Guzmán, F. Jiménez-Gil, J.I. Gámez-Nava, L. González-López, et al.
Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis.
J Rheumatol, 22 (1995), pp. 2120-2125
[39.]
J.R. Harding, I.W. McCall, W.M. Park, B.F. Jones.
Fracture of the cervical spine in ankylosing spondylitis.
Br J Radiol, 58 (1985), pp. 3-7
[40.]
J.D. Bartleson, M.D. Cohen, T.M. Harrington, N.P. Goldstein, W.W. Ginsburg.
Cauda equina syndrome secondary to long-standing ankylosing spondylitis.
Ann Neurol, 14 (1983), pp. 662-669
[43.]
S. Donnelly, D.V. Doyle, A. Denton, I. Rolfe, E.V. McCloskey, T.D. Spector.
Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis.
Ann Rheum Dis, 53 (1994), pp. 117-121
[44.]
R. Will, R. Palmer, A.K. Bhalla, F. Ring, A. Calin.
Osteoporosis in early ankylosing spondylitis: a primary pathological event?.
Lancet, 2 (1989), pp. 1483-1485
[45.]
J. Gratacós, A. Collado, F. Pons, M. Osaba, R. Sanmartí, M. Roque, et al.
Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study.
Arthritis Rheum, 42 (1999), pp. 2319-2324
[46.]
C. Cooper, L. Carbone, C.J. Michet, E.J. Atkinson, W.M. O’Fallon, L.J. Melton 3ed..
Fracture risk in patients with ankylosing spondylitis: a population based study.
J Rheumatol, 21 (1994), pp. 1877-1882
[47.]
S.H. Ralston, G.D. Urquhart, M. Brzeski, R.D. Sturrock.
Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis.
BMJ, 300 (1990), pp. 563-565
[48.]
R. Bessant, C. Harris, A. Keat.
Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis.
J Rheumatol, 30 (2003), pp. 779-782
[49.]
F. Allali, M. Breban, R. Porcher, J.F. Maillefert, M. Dougados, C. Roux.
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α.
Ann Rheum Dis, 62 (2003), pp. 347-349
[50.]
H. Marzo-Ortega, D. McGonagle, G. Haugeberg, M.J. Green, S.P. Stewart, P. Emery.
Bone mineral density improvement in spondyloarthropathy after treatment with etanercept.
Ann Rheum Dis, 62 (2003), pp. 1020-1021
[51.]
Briot K, Gamero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α therapy. Ann Rheum Dis. Published online first january 7, 2005.doi:10.1136/ard.2004.028670.
Copyright © 2005. Elsevier España S.L. Barcelona
